ADMA BIOLOGICS, INC.

ADMA Biologics, Inc. (NASDAQ: ADMA) is a U.S.-based end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The company operates through two primary business segments: ADMA BioManufacturing and Plasma Collection Centers.

Through ADMA BioManufacturing, the company manufactures and markets three FDA-approved products. ASCENIV is an intravenous immune globulin product indicated for treating Primary Humoral Immunodeficiency in adults and adolescents, approved in April 2019 with commercial sales commencing in October 2019. BIVIGAM is an IVIG product approved for treating primary immunodeficiency in adults and pediatric patients two years and older, with FDA approval received in May 2019. Nabi-HB is a hyperimmune globulin indicated for acute exposure to blood containing hepatitis B surface antigen, approved by the FDA in March 1999. The company also develops pipeline candidates including SG-001, an S. pneumoniae hyperimmune globulin currently in preclinical development.

Manufacturing operations are conducted at an FDA-licensed plasma fractionation and purification facility in Boca Raton, Florida with peak annual processing capability of up to 600,000 liters. In April 2025, the FDA approved the company's yield enhancement production process for ASCENIV and BIVIGAM, which increases production yields by approximately twenty percent from the same starting plasma volume.

The Plasma Collection Centers segment operates plasma collection facilities that provide source plasma for manufacturing and supply plasma to third-party customers. As of December 31, 2025, the company operated ten FDA-licensed plasma collection facilities, with plans to divest three centers while maintaining seven facilities and entering into long-term plasma supply agreements with the purchaser.

The company's targeted patient populations include immune-compromised individuals with underlying immune deficiency disorders or those medically immunosuppressed. The U.S. market for immune and hyperimmune globulin products was approximately thirteen billion dollars in 2024 and is projected to exceed thirty billion dollars by 2033. The company website is www.admabiologics.com.